Related references
Note: Only part of the references are listed.Comparison of oral versus intravenous etoposide in the management of small-cell lung cancer; A real-world, population-based study
Hatim Karachiwala et al.
CLINICAL RESPIRATORY JOURNAL (2021)
A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer
Jin-Hyoung Kang et al.
BRITISH JOURNAL OF CANCER (2021)
The rediscovery of platinum-based cancer therapy
Sven Rottenberg et al.
NATURE REVIEWS CANCER (2021)
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Wenhua Liang et al.
LANCET ONCOLOGY (2020)
Clinical Characteristics of Coronavirus Disease 2019 in China
W. Guan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China
L. Zhang et al.
ANNALS OF ONCOLOGY (2020)
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy
Giacomo Grasselli et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: Updated results from a phase Ib-II trial.
Santiago Ponce Aix et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
Jose Trigo et al.
LANCET ONCOLOGY (2020)
Cancer guidelines during the COVID-19 pandemic
Talha Khan Burki
LANCET ONCOLOGY (2020)
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China
Jing Yu et al.
JAMA ONCOLOGY (2020)
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
G. Curigliano et al.
ANNALS OF ONCOLOGY (2020)
IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer
S. V. Liu et al.
ANNALS OF ONCOLOGY (2020)
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2020)
A brief report on combination chemotherapy and anti-programmed death (ligand) 1 treatment in small-cell lung cancer: Did we choose the optimal chemotherapy backbone?
Joanne M. Mankor et al.
EUROPEAN JOURNAL OF CANCER (2020)
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
Nathalie Baize et al.
LANCET ONCOLOGY (2020)
Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment ofExtensive-StageSmall Cell Lung Cancer
Barbara Melosky et al.
ONCOLOGIST (2020)
Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials
Francesco Facchinetti et al.
CANCERS (2020)
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Vivek Subbiah et al.
LUNG CANCER (2020)
First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
Thierry Landre et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
Anna F. Farago et al.
CANCER DISCOVERY (2019)
Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity
Wei Xie et al.
ONCOIMMUNOLOGY (2019)
471PLurbinectedin (LUR) in combination with irinotecan (IRI) in patients (pts) with advanced solid tumours
S Ponce Aix et al.
ANNALS OF ONCOLOGY (2019)
How we treat patients with lung cancer during the SARS-CoV-2 pandemic:primum non nocere
Giuseppe Banna et al.
ESMO OPEN (2019)
Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis
Zi-Li Liu et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
1673PPhase II study of NAB-paclitaxel in sensitive and refractory relapsed SCLC (NABSTER TRIAL)
F Gelsomino et al.
ANNALS OF ONCOLOGY (2018)
Overall Survival with Lurbinectedin Plus Doxorubicin in Relapsed SCLC. Results from an Expansion Cohort of a Phase Ib Trial
M. Forster et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Small-cell lung cancer: what we know, what we need to know and the path forward
Adi F. Gazdar et al.
NATURE REVIEWS CANCER (2017)
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer
Shannon C. Leonard et al.
ANTI-CANCER DRUGS (2017)
Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
E. Calvo et al.
ANNALS OF ONCOLOGY (2017)
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
Cristina Belgiovine et al.
BRITISH JOURNAL OF CANCER (2017)
Taxane anticancer agents: a patent perspective
Iwao Ojima et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2016)
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
Yan Sun et al.
BMC CANCER (2016)
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Naiyer A. Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era A Patient-Level Analysis of Southwest Oncology Group Trials
Primo N. Lara et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Macrophages of M1 phenotype have properties that influence lung cancer cell progression
Alexander Hedbrant et al.
TUMOR BIOLOGY (2015)
Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
Ashish V. Kalra et al.
CANCER RESEARCH (2014)
First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors
Maria Elena Elez et al.
CLINICAL CANCER RESEARCH (2014)
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
Joachim von Pawel et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase
Marjorie G. Zauderer et al.
LUNG CANCER (2014)
Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine- DNA Methyltransferase as a Potential Biomarker
M. Catherine Pietanza et al.
CLINICAL CANCER RESEARCH (2012)
Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
Antonio Rossi et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients
Gun Min Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062
Mary E. R. O'Brien et al.
EUROPEAN JOURNAL OF CANCER (2011)
Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy
Robert Jotte et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Small-cell lung cancer
Jan P. van Meerbeeck et al.
LANCET (2011)
A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer
Chin Kook Rhee et al.
LUNG CANCER (2011)
Small Cell Lung Cancer: Are We Making Progress?
Jonathan E. Dowell
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2010)
PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity
J. F. M. Leal et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Anticancer oral therapy: Emerging related issues
Giuseppe Luigi Banna et al.
CANCER TREATMENT REVIEWS (2010)
Phase II study of amrubicin and carboplatin in patients with the refractory or relapsed small cell lung cancer (SCLC).
T. Hirose et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer
David S. Ettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Development of a highly stable and targetable nanoliposomal formulation of topotecan
Daryl C. Drummond et al.
JOURNAL OF CONTROLLED RELEASE (2010)
A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer
Kyoichi Kaira et al.
LUNG CANCER (2010)
Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402
Akira Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer
Wouter K. De Jong et al.
EUROPEAN JOURNAL OF CANCER (2007)
Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702
H. Okamoto et al.
BRITISH JOURNAL OF CANCER (2007)
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
John R. Eckardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic oncology research group study 0301
Sayaka Onoda et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
Mary E. R. O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer
JR Eckardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: Preliminary results of a phase III trial of the Hellenic Oncology Research Group
Michail Ignatiadis et al.
CLINICAL LUNG CANCER (2005)
Chemopotentiation by PARP inhibitors in cancer therapy
L Tentori et al.
PHARMACOLOGICAL RESEARCH (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics
JP Sculier et al.
BRITISH JOURNAL OF CANCER (2001)
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis
C Mascaux et al.
LUNG CANCER (2000)
Share Paper
